Neurology studies are highly complex trials that require the collection of substantial amounts of data. Neurology studies that rely on ophthalmic assessments need consistent, protocol-adherent execution to protect data quality, endpoint integrity, and site participation. Recently, neurology clinical trials have increasingly relied on ocular biomarkers. Visual fields, optical coherence tomography (OCT), and electroretinograms (ERGs) are particularly useful in these studies. They help monitor disease progression and even address drug safety concerns to prevent adverse events.
However, it can be a challenge to perform ophthalmic assessments. The required instruments must be calibrated correctly and operated by trained technicians to maintain data integrity.
When conducting ophthalmic assessments for neurology trials, clinical trial data quality can suffer due to inconsistencies across test sites. Endpoint integrity is then put at risk, making steps like obtaining FDA approval for new treatments more difficult.
To protect the quality of clinical trial data in neurology studies that use ophthalmic assessments, sponsors and clinical research organizations (CROs) must ensure specialized ophthalmic execution that is protocol-adherent across every site. But what does this mean when dealing with multiple trial sites? Here’s what you need to know.
Why Ocular Endpoints Matter in Neurology Trials
A clinical research study in neurology can obtain essential data through ocular endpoints. Ocular assessments are non-invasive procedures that offer access to neurological data. The eye is seen as a window into the central nervous system. All manner of information can be gleaned without surgical interventions.
The retina and optic nerve are extensions of the brain. Because they contain glial cells and unmyelinated nerve fibers, they provide a clear view of how a neurological drug is performing. They offer insight into side effects, too. This is the case when OCT, ERGs, and fundus photography endpoints are incorporated into the study design.
Ocular damage is often visible before cognitive function issues begin in conditions like Alzheimer’s. Monitoring ocular biomarkers can make it easier to diagnose conditions such as Parkinson’s disease or multiple sclerosis (MS). The sooner a diagnosis is made, the sooner treatment can begin. Getting participants in trials at the earliest stages of a disease can help develop management therapies.
By including ocular endpoints in your study, you can obtain quantifiable, concrete data. Eye movement tracking, for example, offers a direct look at cranial nerve and central nervous system health.
Until recently, traditional neurological endpoints, such as subjective motor surveys, required years to yield results. Ocular assessments can provide data in much shorter periods. Being able to speed up results while maintaining accuracy can propel your study to the forefront of the industry.
Analyzing how functional and structural markers change during the trial can make it easier to gauge whether the treatment or medication is effective. Making these inferences rapidly helps to adjust the trial as needed.
One of the most important reasons ocular endpoints matter in these trials is regulatory requirements. The FDA is now placing significant emphasis on ocular endpoints in neurology studies. These assessments can serve as markers of efficacy and patient safety. Using them can help with regulatory compliance.
Book a call to further understand how ocular assessments could impact data collection.
How Inconsistent Ophthalmic Assessments Threaten Data Quality
Whether you’re running a Phase 1 or Phase 3 trial, clinical trial data quality depends on consistency. That’s not easy to achieve in any trial, but it can be even more challenging with ophthalmic assessments.
For one, the equipment’s calibration and the methods used to obtain data can differ from one trial site to another. Technicians, too, may have varying training that affects how they obtain data. Both of these factors could mean that there are variables distorting the information you gather.
Data accuracy can also suffer if standard operating procedures aren't in place. This can occur if there are off-site assessments, which bring even more variability into the equation. Differences in time and location can inevitably impact data.
Participants can also introduce clinical data management issues. If they are faced with travel burdens, meaning they have to travel long distances for assessments, they may miss appointments. These actions result in gaps in data collection. Gaps in data weaken the study’s results. Audit trails could also be impacted.
Even if they don’t completely skip appointments, participants could be late in completing their assessments. When measuring delicate changes to nerve fibers, any delay could skew the results.
How Ophthalmic Demands Affect Site Participation and Data Consistency
Neurological studies typically require ophthalmic assessments, but neurologists typically don’t specialize in this field. They might not know how to operate the necessary equipment and may not understand the variables that could impact results. These issues could spell trouble for any study.
Principal investigators may hesitate to join the trial if you don’t have a solution on hand for such challenges. If that occurs, then your participant pool can shrink. Your site network could be affected, too, curtailing your study’s reach.
If you’re unable to have enough testing sites, it could affect your data management plan. You may not have enough sites to provide a sufficiently wide range of results. A weaker dataset may reduce the reliability of the trial’s endpoints. That could spell trouble for quality assurance and affect your chances of receiving FDA approval.
This is where having an integrated ophthalmic partner can be invaluable. Through protocol-adherent assessments and trained ophthalmic clinicians, these partners keep principal investigators engaged with the study. They also protect consistency and ocular endpoint protection across testing sites so that regulatory bodies like the FDA are satisfied with the accuracy of the results, and oversight bodies like the Institutional Review Board (IRB) maintain confidence in the trial's conduct.
Get a trial rescue plan today to better protect your results.
Protecting Data Quality Through Standardized Ophthalmic Execution
To safeguard clinical trial data quality and ensure good clinical practice (GCP) in ocular assessments, specialized ophthalmic execution is key. Vitally, it's necessary to ensure consistency in the calibrated equipment you rely on. The equipment must be the same and calibrated in exactly the same manner across all testing sites.
Image acquisition should follow strict protocols, as well. These guidelines can help reduce variability in the collected data. Having electronic data capture (EDC) protocols in place can go a long way toward this.
These protocols can provide real-time data verification, which limits manual data entry errors. 20/20 Onsite-supported studies have achieved approximately 98% data submission accuracy. Anything less than that and you could face data integrity problems.
Clinical trial solutions to protect data quality should also include trained ophthalmic clinicians experienced in conducting protocol-adherent assessments. This assists with inter-rater reliability.
Ensuring clinical trial data quality helps keep treatments as safe as possible while also remaining compliant with FDA regulations. Data integrity should always be a focus, and standardized ocular execution can help you obtain it.
How Point-of-Need Delivery Strengthens Neurology Trial Data
One way to manage the complexities of neurology trial data collection is to rely on point-of-need delivery. This approach brings specialized ophthalmic execution and calibrated equipment directly to participants' locations.
Point-of-need delivery serves numerous purposes. Importantly, this trial design reduces the travel burden placed on participants. They will not have to travel significant distances for their assessments.
Not only does this benefit patients, but it also helps to prevent them from missing appointments. Any time a patient doesn’t attend an assessment, they leave a gap in the trial data. Enough of these gaps can put your trial at risk.
With point-of-need delivery, you can access trial sites in 48 states. That opens the door to more participants and a wider dataset.
Dropout rates are a widespread issue. It’s difficult enough to recruit participants, but if they struggle with the trial, they can drop out halfway through. Replacing them can be costly and leave data gaps that could hurt your results.
One of the most common reasons people leave their studies is the burden of travel. With point-of-need delivery, the average miles they will have to travel for assessments is greatly reduced.
That reduced travel time is crucial. In standard clinical trials, the average dropout rate is 30%. In trials that use point-of-need delivery, it is 9%.
No matter how dispersed your participants are, point-of-need delivery maintains strict protocols for consistency. It integrates with existing sponsor, CRO, and site systems rather than replacing them, reinforcing established governance while protecting endpoint integrity.
Get in touch with the team to discover more about this approach today.
Protect Your Neurology Endpoints From Ophthalmic Data Risk
If you’re in the planning stages of a neurology study that will rely on ophthalmic data, knowing the risks of inconsistency is vital. If you’re not able to maintain standard protocols throughout trial sites, the data may become harder to compare, interpret, or rely on for endpoint analysis.
One of the most effective ways of preventing this problem is to turn to execution partners that provide point-of-need delivery. At 20/20 Onsite, we offer specialized ophthalmic execution with single-call accountability. We provide calibrated equipment operated by trained ophthalmic clinicians, while always ensuring our work integrates with your existing sponsor, CRO, and site systems.
If you’re concerned about data integrity, it’s time to request a protocol review. Our team can identify data risks and provide options to address them. Standardized execution protects endpoint integrity, and we can make that a reality.
Identify ophthalmic data quality risks before they threaten your endpoints. Schedule a consultation.